ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ケトロラク

Ketorolac

HCID 3826
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
66635-83-4
標準SMILES
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
InChIKey
OZWKMVRBQXNZKK-UHFFFAOYSA-N
分子式
C15H13NO3
平均分子量
255.27 g/mol
単同位体質量
255.08954328

概要

Ketorolac is a racemate comprising equimolar amounts of (R)-(+)- and (S)-()-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-() enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure. It has a role as a non-steroidal anti-inflammatory drug, an analgesic, a cyclooxygenase 2 inhibitor and a cyclooxygenase 1 inhibitor. It contains a (R)-ketorolac and a (S)-ketorolac. It is a conjugate acid of a ketorolac(1-).

名称と識別子

優先名称
Ketorolac
IUPAC
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
現地名
ケトロラク
英語名
Ketorolac
分子式
C15H13NO3
分子量
255.27

名称と別名

ketorolac74103-06-3KetorolacoKetorolacum(+-)-Ketorolacrac-ketorolacDTXSID8023189(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acidCHEBI:6129YZI5105V0L1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydroDTXCID503189
名称をさらに表示
ケトロラク(S)-ケトロラック(1S)-5-ベンゾイル-2,3-ジヒドロ-1H-ピロリザイン-1-カルボン酸(S)-(-)-ケトロラックケトロラク酸(1S)-5-ベンゾイル-2,3-ジヒドロ-1H-ピロリザイン-1β-カルボン酸rac-(1R*)-5-ベンゾイル-2,3-ジヒドロ-1H-ピロリザイン-1-カルボン酸ケトロラック(-)-ケトロラック5-ベンゾイル-2,3-ジヒドロ-1H-ピロリジン-1-カルボン酸Ketorolac acidFluoxetinAcular(S)-KetorolacDolacrs37619LixidolTm-asynToratex
1H-Pyrrolizine-1-carboxylic acid, 2,3-dihydro-5-benzoyl-, (+-)-5-(benzoyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acidRefChem:55433M01AB15S01BC055-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acidKetoralac66635-83-4

物性

構造計算による物性補完中

XLogP
1.9
極性表面積
59.3 Ų
水素結合供与体数
1
水素結合受容体数
3
回転可能結合数
3
重原子数
19
形式電荷
0
複雑度
376

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Analgesics and anti-inflammatories

Pharmaceuticals

LogP · 2 件

2.1

2.72

Solubility5.13e-01 g/L
Human Drugs · 2 件

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

Pharmaceuticals

Melting Point · 2 件

162-165 °C (tromethamine salt)

165 - 167 °C (tromethamine salt)

Physical DescriptionSolid
Dissociation Constants · 2 件

3.49

3.5

物理化学的性質

融点
160 · 160-161°C
沸点
493.2 · 493.2±40.0 °C(Predicted)
比重(密度)
1.33 · 1.33±0.1 g/cm3(Predicted)
貯蔵温度

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 7 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationREACH registered substance: 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid (EC: 616-049-1)
Hazard Classes and CategoriesAcute Tox. 3 (100%)

毒性情報

Hepatotoxicity · 1 件

Prospective studies show that up to 1% of patients taking ketorolac experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation. Marked aminotransferase elevations above 3 times the upper limit of normal (ULN) occur in less than 1% of patients. Clinically apparent liver injury with jaundice from ketorolac has not been described in any detail so that the latency, clinical features and prognosis of injury is unknown. Ketorolac is not mentioned as an etiologic agent in large case series on drug induced liver injury or acute liver failure from the United States. However, the antiplatelet activity of ketorolac can lead to complications mostly due to platelet dysfunction and bleeding, and several instances of hepatic rupture and subcapsular hepatic hematomas have been reported with its use which might present clinically as acute liver injury.

Adverse EffectsDrug-Drug Interactions

化学と産業

薬理情報

ATC Code · 5 件

S01BC05

M - Musculo-skeletal system

S - Sensory organs

QM - Musculo-skeletal system

QS - Sensory organs

Protein Binding>99% of Ketorolac is plasma protein bound.
Pharmacodynamics · 1 件

Ketorolac is a non-selective NSAID and acts by inhibiting both COX-1 and COX-2 enzymes which are normally responsible for converting arachidonic acid to prostaglandins. The COX-1 enzyme is constitutively active and can be found in platelets, gastric mucosa, and vascular endothelium. On the other hand, the COX-2 enzyme is inducible and mediates inflammation, pain and fever. As a result, inhibition of the COX-1 enzyme is linked to an increased risk of bleeding and risk of gastric ulceration, while the desired anti-inflammatory and analgesic properties are linked to inhibition of the COX-2 enzyme. Therefore, despite it's effectiveness in pain management, ketorolac should not be used long-term since this increases the risk of serious adverse effects such as gastrointestinal bleeding, peptic ulcers, and perforations.

Mechanism of Action · 1 件

Ketorolac inhibits key pathways in prostaglandin synthesis which is crucial to it's mechanism of action. Although ketorolac is non-selective and inhibits both COX-1 and COX-2 enzymes, it's clinical efficacy is derived from it's COX-2 inhibition. The COX-2 enzyme is inducible and is responsible for converting arachidonic acid to prostaglandins that mediate inflammation and pain. By blocking this pathway, ketorolac achieves analgesia and reduces inflammation. Ketorolac is administered as a racemic mixture; however, the "S" enantiomer is largely responsible for it's pharmacological activity.

Biological Half-Life · 1 件

Ketorolac tromethamine is administered as a racemic mixture, therefore the half-life of each enantiomer must be considered. The half life of the S-enantiomer is ~2.5 hours, while the half life of the R-enantiomer is ~5 hours. Based on this data, the S enantiomer is cleared about twice as fast as the R enantiomer.

Metabolism/Metabolites

関連反応

15 件
反応記録を作成
HRID 372229 の反応式
HRID 372229反応物として
HRID 430837 の反応式
HRID 430837生成物として
HRID 430838 の反応式
HRID 430838反応物として
HRID 434532 の反応式
HRID 434532反応物として
HRID 636077 の反応式
HRID 636077反応物として
HRID 636078 の反応式
HRID 636078反応物として
HRID 636079 の反応式
HRID 636079反応物として
HRID 636080 の反応式
HRID 636080反応物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
66635-83-4、74103-06-3
PubChem CID
3826
DTXSID
DTXSID8023189
ChEMBL
CHEMBL469
ChEBI
CHEBI:6129
UNII
YZI5105V0L
EC Number
616-049-1
Nikkaji
J1.487.487I
2 · 2-8°C
溶解性
クロロホルム(微量)、メタノール(微量)
外見
個体
酸解離定数(Pka)
3.49 · 3.49 ±0.02(at 25℃)
色
オフホワイト
水溶解度
183 mg/L · 183mg/L(32℃)
InChI
InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)
InChIKey
OZWKMVRBQXNZKK-UHFFFAOYSA-N
SMILES
N12CCC(C(O)=O)C1=CC=C2C(=O)C1=CC=CC=C1
CAS データベース
74103 · 74103-06-3(CAS DataBase Reference)
EPAの化学物質情報
1 H-Pyrrolizine-1-carboxylic · 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro- (74103-06-3)

化学的性質

化学的特性Light yellow solid

Toxicity Summary · 1 件

High quantities or prolonged use of ketorolac can lead to hepatotoxicity and nephrotoxicity. In addition, ketorolac can cause multiple skin disorders, such as toxic epidermal necrolysis. Anaphylactic shock has been characterized due to ketorolac overdose.

Drug Induced Liver Injury · 6 件

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

ketorolac

Toradol®

NSAIDs

3

less-DILI-concern drugs

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

ridadr
3249
毒性
LD50 orally in mice: ~200 mg/kg (Rooks)
hs_code
2933998090
hazard_class
6.1(a)
packing_group
II
· 1 件

Ketorolac is heavily metabolized via hydroxylation or conjugation in the liver; however, it appears that the key metabolic pathway is glucuronic acid conjugation. Enzymes involved in phase I metabolism include CYP2C8 and CYP2C9, while phase II metabolism is carried out by UDP-glucuronosyltransferase (UGT) 2B7.

FDA Pharmacological Classification · 6 件

YZI5105V0L

KETOROLAC

Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors

Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal

Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug

Established Pharmacologic Class [EPC] - Cyclooxygenase Inhibitor

MeSH Pharmacological Classification · 2 件

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Absorption, Distribution and Excretion · 4 件

Ketorolac is rapidly, and completely absorbed after oral administration with a bioavailability of 80% after oral administration. Cmax is attained 20-60 minutes after administration, and after intramuscular administration, the area under the plasma concentration-time curve (AUC) is proportional to the dose administered. After intramuscular administration, ketorolac demonstrates a time to maximal plasma concentration (tmax) of approximately 45-50 minutes, and a tmax of 30-40 minutes after oral administration. The rate of absorption may be reduced by food; however, the extent of absorption remains unaffected.

Ketorolac is primarily renally eliminated and approximately 92% of the dose can be recovered in the urine with 60% of this proportion recovered unchanged, and 40% recovered as metabolites. In addition 6% of a single dose is eliminated in the feces.

The apparent volume of distribution of ketorolac in healthy human subjects is 0.25 L/kg or less.

The plasma clearance of ketorolac is 0.021 to 0.037 L/h/kg. Further, studies have illustrated that clearance of oral, IM and IV doses of ketorolac are comparable which suggests linear kinetics. It should also be noted that clearance in children is about double the clearance found in adults.

Cellular LocationsCytoplasm
Metabolite PathwaysKetorolac Action Pathway

用途と製造

UsesUse (kg) in USA (2002): 591
Use ClassificationPharmaceuticals
応用分野 · 2 件

使用antiarrhythmic

一般的な説明Ketorolac tromethamine (Toradol), marketed as a mixture of(R)- and (S)-ketorolac enantiomers, is a potent NSAID analgesicindicated for the treatment of moderately severe, acutepain. It should be noted that the pharmacokinetic dispositionof ketorolac in humans is subject to marked enantioselectivity.Thus, it is important to monitor the individual blood levelsso an accurate assessment of its therapeutic action can bemade correctly. However, it should be noted that, beingone of the conventional NSAIDs with highest risk of GIcomplications, its administration should not exceed 5 days.

上流・下流製品情報

上流原料

水素化ナトリウム2-アミノエタノールn-オクタン無水酢酸N,N-ジメチルホルムアミドピロール2-ブロモエタナールAcetylacetone二酢酸マンガン(II)·4水和物メチルスルフィドN-クロロこはく酸イミドグルタル酸ジメチル過マンガン酸カリウム酢酸Esterified product2-ベンゾイル-1H-ピロールジクロロエタンMonoester